Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease
暂无分享,去创建一个
Catherine Sackley | Bridget Penhale | Carl E Clarke | C. Sackley | C. Clarke | H. Flaherty | D. J. Daley | B. Penhale | K. Deane | R. Pascoe | Stacey Storey | Katherine H O Deane | David J Daley | Helen Flaherty | Roland Pascoe | Stacey Storey
[1] Bill Bynum,et al. Lancet , 2015, The Lancet.
[2] PD Med Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial , 2014, The Lancet.
[3] A. Gray,et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. , 2014, Lancet.
[4] T. Abma,et al. Living with Parkinson's disease: priorities for research suggested by patients. , 2014, Parkinsonism & related disorders.
[5] P. Myint,et al. Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: a randomised controlled trial , 2014, International journal of clinical practice.
[6] Hannah Cook. Parkinson's disease society. , 2013, Nursing older people.
[7] B. Bloem,et al. The impact of occupational therapy in Parkinson’s disease: a randomized controlled feasibility study , 2013, Clinical rehabilitation.
[8] P. Myint,et al. Systematic review on factors associated with medication non-adherence in Parkinson's disease. , 2012, Parkinsonism & related disorders.
[9] M. Brady,et al. Comparison of speech and language therapy techniques for speech problems in Parkinson's disease. , 2012, The Cochrane database of systematic reviews.
[10] Carl E Clarke,et al. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease. , 2012, The Cochrane database of systematic reviews.
[11] Catherine Sackley,et al. Physiotherapy intervention in Parkinson’s disease: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.
[12] Catherine Sherrington,et al. Balance and falls in Parkinson's disease: A meta‐analysis of the effect of exercise and motor training , 2011, Movement disorders : official journal of the Movement Disorder Society.
[13] C. Clarke,et al. Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[14] C. Counsell,et al. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. , 2009, The Cochrane database of systematic reviews.
[15] A. Grant,et al. Prioritizing research: Patients, carers, and clinicians working together to identify and prioritize important clinical uncertainties in urinary incontinence , 2009, Neurourology and urodynamics.
[16] R. Hughes. The NHS Constitution , 2009 .
[17] I. Chalmers. Confronting therapeutic ignorance , 2008, BMJ : British Medical Journal.
[18] H. Thornton. Patient and public involvement in clinical trials , 2008, BMJ : British Medical Journal.
[19] J. Ferreira,et al. Dopamine agonist therapy in early Parkinson's disease. , 2008, The Cochrane database of systematic reviews.
[20] C. Ramaker,et al. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease. , 2007, The Cochrane database of systematic reviews.
[21] Ann Ashburn,et al. A meta‐analysis of six prospective studies of falling in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[22] K. Dashtipour,et al. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. , 2007, Clinical therapeutics.
[23] H. Taylor,et al. Occupational therapy for patients with Parkinson's disease. , 2007, The Cochrane database of systematic reviews.
[24] B. Delaney. Is society losing control of the medical research agenda? , 2006, BMJ : British Medical Journal.
[25] J. Ioannidis,et al. Origin and funding of the most frequently cited papers in medicine: database analysis , 2006, BMJ : British Medical Journal.
[26] J. Scadding,et al. The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials , 2004, The Lancet.
[27] C. Clarke,et al. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. , 2004, The Cochrane database of systematic reviews.
[28] J. Kemm. Well informed uncertainties about the effects of treatment , 2004, BMJ : British Medical Journal.
[29] Iain Chalmers,et al. Well informed uncertainties about the effects of treatments , 2004, BMJ : British Medical Journal.
[30] A. Lees,et al. Anticholinergics for symptomatic management of Parkinson's disease. , 2002, The Cochrane database of systematic reviews.
[31] Paul Dieppe,et al. Relation between agendas of the research community and the research consumer , 2000, The Lancet.
[32] R. Cumming,et al. Prospective study of the impact of fear of falling on activities of daily living, SF-36 scores, and nursing home admission. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.
[33] M. Baker. The Parkinson's Disease Society. , 1988, Geriatric nursing and home care.
[34] J. B. Gregg,et al. DEPARTMENT OF HEALTH. , 1910, California state journal of medicine.